Biogen Pharmachem Industries L
BIOGEN.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$273.79M
Close$
$0.03
88.6% downside
Current Fair Value
88.6% downsideOvervalued by 88.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $273.79 Million |
|---|---|
| Enterprise Value | $270.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.01 |
| Beta | -0.53 |
| Outstanding Shares | 1,053,037,000 |
Return
| Return on Equity | -0.17% |
|---|---|
| Return on Assets | -0.17% |
| Return on Invested Capital | -0.17% |
Valuation & Multiples
| P/E Ratio | -92.86 |
|---|---|
| PEG | 111.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 18.55 |
| Enterprise Value to EBIT | -162.31 |
| Enterprise Value to Net Income | -163 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biogen Pharmachem Industries L
0
CEO: Kelash Bunkar Biogen Pharmachem Industries Ltd. began its operations on July 13, 1995, from its headquarters in Rajkot, India. The company's main business activity focuses on dealing in and trading various shares and securities.